Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment

Wenyin Shi, Erik S. Blomain, Joshua Siglin, Joshua J. Palmer, Tu Dan, Yang Wang, Maria Werner-Wasik, Jon Glass, Lyndon Kim, Voichita Bar Ad, Deepak Bhamidipati, James J. Evans, Kevin Judy, Christopher J. Farrell, David W. Andrews

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Dec 12 2017

Fingerprint

Glioma
Therapeutics
Survival
Re-Irradiation
Bevacizumab
Feasibility Studies
Multivariate Analysis
Prospective Studies
Recurrence

Keywords

  • Bevacizumab
  • Glioblastoma
  • High grade glioma
  • Re-irradiation
  • Stereotactic radiation

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. / Shi, Wenyin; Blomain, Erik S.; Siglin, Joshua; Palmer, Joshua J.; Dan, Tu; Wang, Yang; Werner-Wasik, Maria; Glass, Jon; Kim, Lyndon; Bar Ad, Voichita; Bhamidipati, Deepak; Evans, James J.; Judy, Kevin; Farrell, Christopher J.; Andrews, David W.

In: Journal of Neuro-Oncology, 12.12.2017, p. 1-7.

Research output: Contribution to journalArticle

Shi, W, Blomain, ES, Siglin, J, Palmer, JJ, Dan, T, Wang, Y, Werner-Wasik, M, Glass, J, Kim, L, Bar Ad, V, Bhamidipati, D, Evans, JJ, Judy, K, Farrell, CJ & Andrews, DW 2017, 'Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment', Journal of Neuro-Oncology, pp. 1-7. https://doi.org/10.1007/s11060-017-2709-0
Shi, Wenyin ; Blomain, Erik S. ; Siglin, Joshua ; Palmer, Joshua J. ; Dan, Tu ; Wang, Yang ; Werner-Wasik, Maria ; Glass, Jon ; Kim, Lyndon ; Bar Ad, Voichita ; Bhamidipati, Deepak ; Evans, James J. ; Judy, Kevin ; Farrell, Christopher J. ; Andrews, David W. / Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. In: Journal of Neuro-Oncology. 2017 ; pp. 1-7.
@article{bb69657f3480473f8f8b38918bd9d133,
title = "Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment",
abstract = "Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.",
keywords = "Bevacizumab, Glioblastoma, High grade glioma, Re-irradiation, Stereotactic radiation",
author = "Wenyin Shi and Blomain, {Erik S.} and Joshua Siglin and Palmer, {Joshua J.} and Tu Dan and Yang Wang and Maria Werner-Wasik and Jon Glass and Lyndon Kim and {Bar Ad}, Voichita and Deepak Bhamidipati and Evans, {James J.} and Kevin Judy and Farrell, {Christopher J.} and Andrews, {David W.}",
year = "2017",
month = "12",
day = "12",
doi = "10.1007/s11060-017-2709-0",
language = "English (US)",
pages = "1--7",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment

AU - Shi, Wenyin

AU - Blomain, Erik S.

AU - Siglin, Joshua

AU - Palmer, Joshua J.

AU - Dan, Tu

AU - Wang, Yang

AU - Werner-Wasik, Maria

AU - Glass, Jon

AU - Kim, Lyndon

AU - Bar Ad, Voichita

AU - Bhamidipati, Deepak

AU - Evans, James J.

AU - Judy, Kevin

AU - Farrell, Christopher J.

AU - Andrews, David W.

PY - 2017/12/12

Y1 - 2017/12/12

N2 - Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.

AB - Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.

KW - Bevacizumab

KW - Glioblastoma

KW - High grade glioma

KW - Re-irradiation

KW - Stereotactic radiation

UR - http://www.scopus.com/inward/record.url?scp=85037725596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037725596&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2709-0

DO - 10.1007/s11060-017-2709-0

M3 - Article

C2 - 29235052

AN - SCOPUS:85037725596

SP - 1

EP - 7

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -